Sporn J R, Molinoff P B
J Cyclic Nucleotide Res. 1976;2(3):149-61.
125I-Iodohydroxybenzylpindolol ([125I] IHYP), a potent beta-adrenergic receptor antagonist, has been used to study beta-adrenergic receptors in rat brain. Binding of [125I] IHYP (30 pM) to a membrane fraction min and dissociation took place with a half time of about 16 min. Phentolamine (10(-4) M) decreased non-receptor binding but it had no effect on the binding of [125I] IHYP to beta-adrenergic receptors in cortex, cerebellum or caudate. In the presence of phentolamine specific binding (defined as binding which was blocked by 0.3 muM dl-propranolol) represented 70-85% of total binding. The binding of [125I] IHYP was inhibited by beta-adrenergic agonists and antagonists. d-Stereoisomers were 2-3 orders of magnitude less potent than the corresponding 1-isomers. The denstiy of [125I] IHYP binding sites was studied in membrane fractions from cerebral cortex, cerebellum, and caudate nucleus by means of Scatchard analysis. The K(D) of [125I] IHYP was similar in the three regions studied, and the density of [125I] IHYP binding sites was approximately 50% greater in the cortex and caudate than in the cerebellum. The Hill coefficient for the binding of [125I] IHYP to membranes from cerebral cortex was 1.02. The properties of the binding of [125I] IHYP are similar to those which would be expected of binding to beta-adrenergic receptors in vitro.
125I-碘羟基苄基吲哚洛尔([125I]IHYP),一种强效β-肾上腺素能受体拮抗剂,已被用于研究大鼠脑中的β-肾上腺素能受体。[125I]IHYP(30 pM)与膜组分的结合在30分钟内达到平衡,解离半衰期约为16分钟。酚妥拉明(10^(-4) M)可减少非受体结合,但对[125I]IHYP与皮质、小脑或尾状核中β-肾上腺素能受体的结合无影响。在酚妥拉明存在的情况下,特异性结合(定义为被0.3 μM dl-普萘洛尔阻断的结合)占总结合的70-85%。[125I]IHYP的结合受到β-肾上腺素能激动剂和拮抗剂的抑制。d-立体异构体的效力比相应的l-异构体低2-3个数量级。通过Scatchard分析研究了[125I]IHYP结合位点在大脑皮质、小脑和尾状核膜组分中的密度。[125I]IHYP的解离常数(KD)在所研究的三个区域中相似,[125I]IHYP结合位点的密度在皮质和尾状核中比在小脑中大约高50%。[125I]IHYP与大脑皮质膜结合的希尔系数为1.02。[125I]IHYP结合的特性与体外与β-肾上腺素能受体结合所预期的特性相似。